Ladenburg Thalmann Initiates Coverage on Aviragen Therapeutics(NASDAQ:AVIR)

Ladenburg Thalmann Initiates Coverage on Aviragen Therapeutics(NASDAQ:AVIR). The rating by Ladenburg Thalmann was issued on Sep 21, 2016.

In a different note, H.C. Wainwright said it Initiates Coverage on Aviragen Therapeutics, according to a research note issued on Jul 13, 2016. The shares have been rated ‘Buy’ by the firm.

Aviragen Therapeutics(AVIR) last announced its earnings results on May 5, 2016 for Fiscal Year 2016 and Q3.Company reported revenue of $5.30M. Analysts had an estimated revenue of $1.80M. Earnings per share were $-0.14. Analysts had estimated an EPS of $0.25.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Aviragen Therapeutics - Is it time to Sell?

Top Brokerage Firms are advising their investors on Aviragen Therapeutics. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.